Richter Gedeon Vegyeszeti Gyar Nyrt
XMUN:RIG2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Richter Gedeon Vegyeszeti Gyar Nyrt
XMUN:RIG2
|
HU |
|
Aldeyra Therapeutics Inc
NASDAQ:ALDX
|
US |
|
Azeus Systems Holdings Ltd
SGX:BBW
|
HK |
|
United States Steel Corp
NYSE:X
|
US |
|
Korean Air Lines Co Ltd
KRX:003490
|
KR |
|
Bayerische Motoren Werke AG
XETRA:BMW
|
DE |
|
F
|
Forus SA
SGO:FORUS
|
CL |
|
Perenti Global Ltd
ASX:PRN
|
AU |
|
P
|
Pop Mart International Group Ltd
F:735
|
CN |
|
Establishment Labs Holdings Inc
NASDAQ:ESTA
|
CR |
Richter Gedeon Vegyeszeti Gyar Nyrt
Richter Gedeon is a pharmaceutical company that develops, manufactures, and sells prescription medicines, with a strong focus on treatments for women’s health, central nervous system disorders, and some generic drugs. It also makes active pharmaceutical ingredients and drug products that are used in its own medicines and sold to other drugmakers. Its main customers are hospitals, doctors, pharmacies, health systems, and partner pharma companies in many countries. The company makes money by selling branded medicines, generic products, and active ingredients, and by licensing or partnering on some of its drug programs. That mix gives it both direct sales and business-to-business revenue. Because drug development is slow and heavily regulated, Richter’s business depends on scientific research, manufacturing quality, and approval processes more than on retail-style selling. What makes Richter different is its role as both a medicine developer and a manufacturer of pharmaceutical ingredients. That means it is not just packaging products made elsewhere; it sits deeper in the drug supply chain and can profit from multiple steps, from research to production to sale. For investors, it is best thought of as a specialty drug company with a long-established presence in Central and Eastern Europe and a wider international reach.
Richter Gedeon is a pharmaceutical company that develops, manufactures, and sells prescription medicines, with a strong focus on treatments for women’s health, central nervous system disorders, and some generic drugs. It also makes active pharmaceutical ingredients and drug products that are used in its own medicines and sold to other drugmakers. Its main customers are hospitals, doctors, pharmacies, health systems, and partner pharma companies in many countries.
The company makes money by selling branded medicines, generic products, and active ingredients, and by licensing or partnering on some of its drug programs. That mix gives it both direct sales and business-to-business revenue. Because drug development is slow and heavily regulated, Richter’s business depends on scientific research, manufacturing quality, and approval processes more than on retail-style selling.
What makes Richter different is its role as both a medicine developer and a manufacturer of pharmaceutical ingredients. That means it is not just packaging products made elsewhere; it sits deeper in the drug supply chain and can profit from multiple steps, from research to production to sale. For investors, it is best thought of as a specialty drug company with a long-established presence in Central and Eastern Europe and a wider international reach.
